By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS


Industry
Pharmaceutical






Company News
Threshold Pharmaceuticals, Inc. (THLD) Initiates Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Recurrent Or Metastatic Squamous Cell Carcinomas Of The Head And Neck Or Skin 8/27/2015 11:17:39 AM
Threshold Pharmaceuticals, Inc. (THLD) And ATOMIC Initiate First Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) 8/11/2015 11:10:26 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Second Quarter 2015 Financial And Operational Results 8/3/2015 11:51:29 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Cantor Fitzgerald Healthcare Conference 7/2/2015 10:42:18 AM
ASCO15: Threshold Pharmaceuticals, Inc. (THLD) Presents Encouraging Preliminary Phase 2 Data In Multiple Myeloma At ASCO 6/1/2015 2:41:01 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Jefferies and Co. 2015 Healthcare Conference 5/27/2015 10:34:49 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Clinical Update On Evofosfamide In Relapsed/Refractory Multiple Myeloma To Be Presented At ASCO 2015 5/14/2015 1:08:07 PM
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015 9:56:48 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports First Quarter 2015 Financial And Operational Results 4/30/2015 8:34:32 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance To Conventional EGFR Tyrosine Kinase Inhibitors 4/23/2015 11:45:48 AM
12345678910...
//-->